Tenax Therapeutics, Inc.
TENXAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Aug 11, 2026 | Chardan Capital | $5.00(+205%) | $1.64 | TheFly | |
| Aug 11, 2026 | Canaccord Genuity | $4.00(+191%) | $1.38 | TheFly | |
| Aug 11, 2026 | Guggenheim | $4.00(+191%) | $1.38 | TheFly | |
| Aug 11, 2026 | Leerink Partners | $4.00(+191%) | $1.38 | TheFly | |
| Aug 10, 2026 | Roth Capital | $5.00(+257%) | $1.40 | TheFly | |
| Jul 28, 2026 | Canaccord Genuity | $35.00(+116%) | $16.19 | TheFly | |
| Jun 22, 2026 | Guggenheim | $40.00(+233%) | $12.00 | TheFly | |
| Jun 22, 2026 | Chardan Capital | $27.00(+125%) | $12.00 | TheFly | |
| Dec 17, 2025 | Guggenheim | $25.00(+124%) | $11.16 | TheFly | |
| Sep 8, 2025 | Piper Sandler | Yasmeen Rahimi | $20.00(+231%) | $6.04 | TheFly |
| May 15, 2025 | Guggenheim | Seamus Fernandez | $15.00(+163%) | $5.70 | TheFly |
| Mar 10, 2025 | Leerink Partners | $20.00(+223%) | $6.19 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Guggenheim | downgrade | Buy →Neutral | Aug 31, 2026 |
| Evercore ISI Group | downgrade | Outperform →In Line | Aug 11, 2026 |
| Chardan Capital | downgrade | Buy →Neutral | Aug 11, 2026 |
| Canaccord Genuity | maintain | Buy | Aug 11, 2026 |
| Guggenheim | maintain | Buy | Aug 11, 2026 |
| William Blair | downgrade | Outperform →Market Perform | Aug 10, 2026 |
| Chardan Capital | maintain | Buy | Jul 31, 2026 |
| Cantor Fitzgerald | maintain | Overweight | Jul 29, 2026 |
| Chardan Capital | maintain | Buy | Jul 2, 2026 |
| Cantor Fitzgerald | maintain | Overweight | Jun 24, 2026 |
| Guggenheim | maintain | Buy | Jun 22, 2026 |
| Piper Sandler | maintain | Overweight | Jun 12, 2026 |
| Guggenheim | maintain | Buy | Mar 16, 2026 |
| Guggenheim | maintain | Buy | Dec 17, 2025 |
| Guggenheim | maintain | Buy | Aug 14, 2025 |
| Roth MKM | maintain | Buy | Feb 20, 2024 |
| Roth MKM | maintain | Buy | Nov 13, 2023 |
| Ladenburg Thalmann | upgrade | Neutral →Buy | May 18, 2017 |
Earnings History
Next report: Mar 9, 2027 · EPS est. $-0.34| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 5, 2026 | $-0.31 | $-0.35 | — | — |
| Jul 31, 2026 | $-0.35 | $-0.38 | — | — |
| May 12, 2026 | $-0.35 | $-0.40 | — | — |
| Mar 10, 2026 | $-0.38 | $-1.26 | — | — |
| Nov 12, 2025 | $-0.40 | $-1.33 | — | — |
| Aug 13, 2025 | $-0.27 | $-0.50 | — | — |
| May 14, 2025 | $-0.28 | $-0.48 | — | — |
| Mar 25, 2025 | $-0.18 | $-0.52 | — | — |
News
Lead Plaintiff Deadline: December 28, 2026. Investors who purchased (NASDAQ: TENX) securities between November 13, 2023 and August 7, 2026 may be eligible to recover losses.
New York, New York--(Newsfile Corp. - November 8, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Tenax Therapeutics, Inc. (NASDAQ: TENX) between November 13, 2023 and August 7, 2026, both dates inclusive (the "Class Period"), of the important December 28, 2026 lead plaintiff deadline. SO WHAT: If you purchased Tenax securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through…
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Tenax To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Tenax between November 13, 2023 and August 7, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - Novem…
NEW YORK, Nov. 7, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Tenax Therapeutics, Inc. (NASDAQ: TENX) between November 13, 2023 and August 7, 2026, both dates inclusive (the "Class Period"), of the important December 28, 2026 lead plaintiff deadline. So what: If you purchased Tenax securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee …
NEW YORK, Nov. 07, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Tenax Therapeutics, Inc. (NASDAQ: TENX) between November 13, 2023 and August 7, 2026, both dates inclusive (the “Class Period”), of the important December 28, 2026 lead plaintiff deadline.
New York, New York--(Newsfile Corp. - November 6, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Tenax Therapeutics, Inc. (NASDAQ: TENX) between November 13, 2023 and August 7, 2026, both dates inclusive (the "Class Period"), of the important December 28, 2026 lead plaintiff deadline. SO WHAT: If you purchased Tenax securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through…
NEW YORK, Nov. 6, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Tenax Therapeutics, Inc. ("Tenax" or "the Company") (NASDAQ: TENX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of TENX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.
LOS ANGELES, Nov. 6, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tenax Therapeutics, Inc. ("Tenax" or "the Company") (NASDAQ: TENX) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES--(BUSINESS WIRE)---- $TENX--TENX Investors Have Opportunity to Lead Tenax Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law.
SAN DIEGO, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP, a shareholder-rights law firm, announces that a securities class action lawsuit has been filed in the United States District Court for the Middle District of North Carolina on behalf of investors who purchased or otherwise acquired Tenax Therapeutics, Inc. (NASDAQ: TENX) securities between November 13, 2023 and August 7, 2026, inclusive (the “Class Period”).
Lawsuit alleges Tenax Therapeutics, Inc. made misleading statements to investors from November 13, 2023 to August 7, 2026; lead plaintiff motions are due December 28, 2026 LOS ANGELES, Nov. 6, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz today announced a class action lawsuit against Tenax Therapeutics, Inc. ("Tenax" or the "Company") (NASDAQ: TENX) on behalf of investors who acquired the Company's securities from November 13, 2023 to August 7, 2026.
Lead Plaintiff Deadline: December 28, 2026. Investors who purchased (NASDAQ: TENX) securities between November 13, 2023 and August 7, 2026 may be eligible to recover losses.
Investors in UP Fintech Holding Limited, Tenax Therapeutics, Inc., Everest Group, Ltd., and Yiren Digital Ltd. have upcoming deadlines to seek lead plaintiff appointment in pending securities class actions Investors in UP Fintech Holding Limited, Tenax Therapeutics, Inc., Everest Group, Ltd., and Yiren Digital Ltd. have upcoming deadlines to seek lead plaintiff appointment in pending securities class actions
New York, New York--(Newsfile Corp. - November 6, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Tenax Therapeutics, Inc. ("Tenax" or the "Company") (NASDAQ: TENX) on behalf of investors that purchased or otherwise acquired Tenax securities between November 13, 2023 and August 7, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Tenax and have suffered losses, you may CLICK HERE to contact us.
New York, New York--(Newsfile Corp. - November 5, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Tenax Therapeutics, Inc. (NASDAQ: TENX) between November 13, 2023 and August 7, 2026, both dates inclusive (the "Class Period"), of the important December 28, 2026 lead plaintiff deadline. SO WHAT: If you purchased Tenax securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through…
NEW YORK, Nov. 5, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Tenax Therapeutics, Inc. ("Tenax" or the "Company") (NASDAQ: TENX) and certain officers. The class action, filed in the United States District Court for the Middle District of North Carolina, and docketed under 26-cv-01624, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Tenax securities between November 13, 20…
SAN DIEGO--(BUSINESS WIRE)---- $TENX #TENX--The case alleges that Tenax Therapeutics and its executives made false and/or misleading statements to investors.
BENSALEM, Pa.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. ("Tenax" or the "Company") (NASDAQ: TENX) investors who wish to serve as lead plaintiff in a pending securities fraud class action lawsuit must move the Court by December 28, 2026. The suit was filed on behalf of investors who purchased or otherwise acquired the Company's securities from November 13, 2023 through August 7, 2026, inclusive. The Law Offices of Howard G. Smith today highlighted the deadline in the case, Katz v. Tenax Therapeu…
Notice to Pension Funds, Asset Managers, and Fiduciaries: the lawsuit alleges Tenax overstated TNX-103's clinical prospects while raising $134 million, largely through private placements, before its Phase 3 LEVEL trial missed its primary endpoint. NEW YORK, Nov. 5, 2026 /PRNewswire/ -- SueWallSt notifies institutional investors, ERISA plan fiduciaries, and asset managers that a class action lawsuit has been filed on behalf of purchasers of Tenax Therapeutics, Inc. (NASDAQ: TENX) securities betwe…
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Tenax To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Tenax between November 13, 2023 and August 7, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - Novem…